Ideaya Biosciences, Inc.

Glaxosmithkline Intellectual Property (no. 4) Limited

Marcus Michael Fischer

Claire L Neilan

Michael Patrick Dillon

Janos Botyanszki

Young Eun Choi

Kimberline Yang Gerrick

Kevin Duffy

Disclosed herein are compounds of Formula (I): that inhibit DNA Polymerase Theta (Polθ) activity, in particular inhibit Polθ activity by inhibiting ATP dependent helicase domain activity of Polθ. Also, disclosed are pharmaceutical compositions comprising such compounds and methods of treating and/or preventing diseases treatable by inhibition of Polθ such as cancer, including homologous recombination (HR) deficient cancers.

Thiadiazolyl derivatives as DNA polymerase theta inhibitors and uses thereof

Provided herein is a combination product comprising a methionine adenosyltransferase II alpha (MAT2A) inhibitor and a Type II protein arginine methyltransferase (Type II PRMT) inhibitor. The combination product is useful for the treatment of a variety of cancers, including solid tumors. The combination product is useful for the treatment of any number of MAT2A-associated and/or PRMT-associated diseases.

Combination therapy comprising a MAT2A inhibitor and a type II PRMT inhibitor

Growing community of inventors

South San Francisco, CA, United States of America

Marcus Michael Fischer